Shots:

• Merck spinoff Organon & showed a slight decline in women’s health medications but growth in biosimilar sales in Q3’21. Organon’s lead pipeline product is used to treat endometriosis,
• Additionally, Novartis also consider the spinoff of its biosimilar division, Sandoz as a standalone company. Sandoz currently has eight biosimilars launched globally and 15 more in the pipeline
• Novartis has reported the start of a strategic review of the Sandoz division. The review will explore all options for Sandoz from retaining the business to separation. The review will stop at the end of 2022

Ref: Center for Biosimilars | Image: Merck